Inovio has secured accelerated approval from the FDA for Voceryq to minimise the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP). This approval may enhance treatment options for patients suffering from this condition, potentially reducing the need for surgical interventions. Manufacturers and suppliers in the pharmaceutical sector may need to consider the implications of this approval on market dynamics and patient access to innovative therapies.
Source: pharmaceutical-technology.com · Image: Concor (bisoprolol) made by Nanolek, Russia with Merck branding, Aug 2025 01 by Retired electrician, CC0, via Wikimedia Commons
For investors and analysts:
See in seconds what each company actually manufactures, together with its certificates and compliance status.
This isn’t marketing language — it’s factual data on APIs, FDFs, dossiers, and direct producer contacts.
Open the full market picture for your next decision →
Open the full market picture for your next decision →
